EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sex-Specific Protection of Endothelial Function after Vascular Ischemia/Reperfusion Injury by the Senomorphic Agent Ruxolitinib

Lars Saemann iD, Paula Naujoks, Lotta Hartrumpf, Sabine Pohl, Andreas Simm, Gábor Szabó

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241411727 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lars Saemann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, University Hospital Halle, 06120 Halle, Germany. Hauptthemen laut MEDLINE: Intercellular Adhesion Molecule-1, Reperfusion Injury. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Martin-Luther-University Halle-Wittenberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemia/reperfusion (I/R)-induced endothelial dysfunction occurs in various cardiovascular disorders. I/R injury is partially driven by the release of cytokines. Known for its use in senotherapy, the JAK inhibitor ruxolitinib is able to block the release of cytokines. We investigated the effect of ruxolitinib on the cytokine release and endothelial-dependent vasorelaxation in an in vitro model of I/R. Aortic segments of C57BL/6J mice (N = 12/group) were divided into three groups: control, in vitro I/R (I/R group), and in vitro I/R with ruxolitinib during ischemic incubation (I/R+Ruxo group). We determined cytokine expression. In organ bath chambers, we investigated the maximal endothelial-dependent relaxation to acetylcholine (RmaxACh) and maximal endothelial-independent relaxation to sodium-nitroprusside (RmaxSNP). RmaxACh was decreased in I/R compared to the control (83.6 ± 2.4 vs. 48.6 ± 3.4%; p < 0.05) and I/R+Ruxo (74.4 ± 2.6 vs. 48.6 ± 3.4%; p < 0.05). RmaxSNP was comparable between all groups. IL-10 was detectable only in I/R+Ruxo. CXCL5, CCL2, CCL3, CCL8, CCL11, ICAM-1, IL-1α, IL-7, TNF-α, and G-CSF were decreased or not detectable in I/R+Ruxo. In I/R+Ruxo, ICAM-1 was reduced in rings only from male mice. Treatment of the aorta from mice during in vitro ischemia with the senomorphic agent ruxolitinib reduces cytokine release and protects the endothelium from I/R-mediated dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intercellular Adhesion Molecule-1Reperfusion InjuryFemaleMiceMaleAnimalsSenotherapeuticsMice, Inbred C57BLEndotheliumVasodilationAcetylcholineCytokinesEndothelium, VascularNitrilesPyrazolesPyrimidines

Stichwörter der Autor:innen

JAKSTATageingendotheliumischemia/reperfusion injuryproinflammatory cytokinesruxolitinibsenescencesenescence-associated secretory phenotype (SASP)senomorphicssenotherapy

Substanzen

Intercellular Adhesion Molecule-1SenotherapeuticsAcetylcholineCytokinesruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Cardiac Surgery, University Hospital Halle, 06120 Halle, Germany.
  • Department of Cardiac Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.

ORCID-Profile: Lars Saemann

Förderung

  • Martin-Luther-University Halle-Wittenberg

Zitieren

APA

Saemann, L., Naujoks, P., Hartrumpf, L., Pohl, S., Simm, A., & Szabó, G. (2023). Sex-Specific Protection of Endothelial Function after Vascular Ischemia/Reperfusion Injury by the Senomorphic Agent Ruxolitinib. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411727

Vancouver

Saemann L, Naujoks P, Hartrumpf L, Pohl S, Simm A, Szabó G. Sex-Specific Protection of Endothelial Function after Vascular Ischemia/Reperfusion Injury by the Senomorphic Agent Ruxolitinib. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411727

BibTeX
@article{Saemann2023,
  author = {Saemann, Lars and Naujoks, Paula and Hartrumpf, Lotta and Pohl, Sabine and Simm, Andreas and Szabó, Gábor},
  title = {Sex-Specific Protection of Endothelial Function after Vascular Ischemia/Reperfusion Injury by the Senomorphic Agent Ruxolitinib},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241411727}
}
Kostenlos starten →